Welcome to our dedicated page for Jyong Biotech Ltd. SEC filings (Ticker: MENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jyong Biotech Ltd. (Nasdaq: MENS) SEC filings page on Stock Titan is designed to help readers review the company’s U.S. regulatory disclosures in one place. As a foreign private issuer in the biotechnology sector focused on plant-derived drugs for urinary system diseases, Jyong Biotech uses SEC filings to describe its business, risk factors, pipeline, and capital-raising activities.
Key documents for MENS include the registration statement on Form F-1 related to its initial public offering and subsequent reports such as Forms 6-K, which the company references in its news releases. These filings provide detail on the company’s lead botanical drug candidates, including MCS-2 and MCS-8, its clinical trial programs in BPH, LUTS, and prostate cancer prevention, and its intended use of IPO proceeds for Phase III and earlier-stage trials, regulatory submissions, and general corporate purposes.
Through Stock Titan, users can access real-time updates from EDGAR as new MENS filings are posted, including prospectuses, current reports, and other required disclosures. AI-powered summaries help explain the structure and implications of lengthy documents, highlighting sections related to clinical development plans, intellectual property, regional licensing strategies, and financial commitments.
Investors interested in insider activity and governance can also use SEC data to review information on share offerings and other transactions as disclosed in Jyong Biotech’s filings. While specific forms such as Form 4 or proxy statements may be more limited for some foreign issuers, the available filings still provide context on ownership, potential dilution, and board-level decisions.
By using the MENS SEC filings page with AI-assisted insights, readers can more easily interpret Jyong Biotech’s regulatory disclosures, understand how its botanical drug pipeline is described to regulators, and see how capital raised on Nasdaq is allocated across its development programs.
Jyong Biotech Ltd. files its Form 20-F for the year ended December 31, 2025, describing a pre-revenue biotech focused on Botreso, a botanical drug candidate initially targeting BPH/LUTS. As of December 31, 2025, it had 76,027,667 ordinary shares outstanding.
The company highlights that its prospects depend heavily on successfully obtaining regulatory approval and commercializing Botreso and a small pipeline of botanical candidates. The U.S. FDA has concluded that one pivotal Phase III trial with API-1 failed to show a statistically significant benefit versus placebo, and the original API-1 source is no longer available. Jyong is now seeking FDA acceptance of comparability between API-1 and a new API-2 and may need additional Phase III and PK studies, or even to repeat earlier-stage trials, which could materially delay development and raise costs.
The filing also discloses substantial legal exposures in China. A final judgment in the Taizhou investment dispute leaves Jyong and affiliates jointly liable for about USD 19.4 million, and additional disputes over land use and subsidies have led to reclamation of land, repayment of a RMB 12.0 million subsidy and liquidated damages. Management notes that a large portion, or potentially all, IPO proceeds may be required to satisfy these obligations, constraining funds available for research and development. The company further flags macroeconomic and geopolitical risks, including tensions involving Taiwan and the PRC, as additional uncertainties.
Jyong Biotech Ltd. received a major ownership disclosure showing that Perfect Minds Co., Ltd. and related entities beneficially own 25,349,500 ordinary shares, or 33.34% of the company’s ordinary shares, based on 76,027,667 shares outstanding as of April 24, 2026.
Perfect Minds, a Seychelles holding company, directly holds the shares. It is wholly owned by Innovation Global Group Limited, which in turn is owned by The Innovation Trust, for which Unity Trust Limited acts as trustee. Ms. Kuo Fu‑Feng, the issuer’s Chief Executive Officer and Chairwoman, is settlor of the trust and sole director of Perfect Minds and has sole voting and dispositive power over these shares.
The stake was acquired for approximately $5,760,075, funded by Ms. Kuo. The reporting persons state they hold the shares for investment purposes and, aside from what is described, do not currently have additional plans tied to corporate actions listed under Item 4.
Jyong Biotech Ltd. CFO files initial ownership report. CFO ZHANG WEI (VIVI) filed a Form 3 as an officer of Jyong Biotech Ltd. (ticker MENS). The filing lists her as Chief Financial Officer and does not report any share purchases, sales, or other transactions.
Jyong Biotech Ltd. CEO Fu-Feng Kuo filed an initial Form 3 reporting indirect beneficial ownership of 25,349,500 ordinary shares of the company. These shares are held through Perfect Minds Co., Ltd., which is ultimately owned via The Innovation Trust, where Ms. Kuo has authority over voting and investment decisions.
Jyong Biotech Ltd. director Hsu Ming Tsan filed an initial statement of beneficial ownership. The filing reports direct ownership of 3,000 shares of Common Stock. This Form 3 is a disclosure of existing holdings and does not show any recent purchase or sale activity.
Jyong Biotech Ltd. director Hsu Feng-Lin has reported initial ownership of the company’s shares. The Form 3 filing lists 3,000 shares of Common Stock held with direct ownership. This is a baseline disclosure of holdings and does not reflect a new purchase or sale.
Jyong Biotech Ltd. director Hsu Feng-Lin filed an initial ownership report showing holdings of the company’s common stock. The filing lists direct beneficial ownership of 3,000 shares of Common Stock following the reported entry, providing a baseline of this director’s equity position in the company.
Jyong Biotech Ltd. director Fan Hung-Shu filed an initial statement of beneficial ownership on Form 3 for company shares. The filing establishes this person’s insider status as a director but does not report any insider purchase, sale, or other transaction in the issuer’s securities.
Jyong Biotech Ltd. director Chi Pang-Chieh has filed a Form 3 as a reporting person for the company. The filing shows no reportable transactions and no listed holdings, with transaction counts and share amounts all recorded as zero in this initial ownership statement.
Jyong Biotech Ltd. appointed Wei (Vivi) Zhang as its new Chief Financial Officer, effective February 6, 2026, replacing former CFO Alfred Ying. The change places an experienced capital markets and public-company finance executive in charge of the company’s financial leadership.
Ms. Zhang has led initial public offerings, fundraising activities and finance functions for listed companies. She previously served as Chief Financial Officer and director at Global Mofy AI Limited from 2019 to January 2024 and holds an accounting degree from the University of South Australia and an MBA from the University of Oxford.